GLP-1 Drugs for Teenagers: What the FDA Has Approved and What the Evidence Shows

Regulatory status: what is approved for adolescents

Semaglutide (Wegovy)

The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adolescents aged 12 years and older with obesity (BMI at or above the 95th percentile for age and sex) in December 2022.

The approval was based on the STEP TEENS trial: a 68-week placebo-controlled RCT in 201 adolescents aged 12–17 with obesity (average BMI ~37). Findings:

• Average weight reduction of 16.1% on semaglutide vs 0.6% on placebo at 68 weeks
• 45% of semaglutide patients achieved at least 20% weight reduction vs 3% on placebo
• Improvement in cardiometabolic markers (HbA1c, lipids, blood pressure)
• Side effects similar to adults: predominantly GI (nausea, vomiting, diarrhoea)

The prescribing label for adolescents includes the same warnings as the adult label: black-box thyroid C-cell tumour warning, pancreatitis, gallbladder disease.

Tirzepatide (Zepbound)

The FDA approved tirzepatide (Zepbound) for adolescents aged 12 years and older with obesity in 2024, based on Phase 3 data from the SURMOUNT TEEN trial. Adolescent weight loss outcomes were comparable to the adult SURMOUNT data, with similar GI side effect profile.

Liraglutide (Saxenda)

Saxenda (liraglutide 3 mg daily) received FDA approval for adolescents aged 12 and older in 2020 — the first GLP-1 approved for adolescent obesity. Efficacy is more modest than semaglutide or tirzepatide; it has largely been superseded in clinical practice but remains available.

What "approved for adolescents" means in practice

FDA approval establishes that the drug is safe and effective for the indicated population and can be marketed and prescribed legally. It does not mean:

• The drug will be covered by insurance for adolescents (payer coverage may differ from adult coverage and often lags approval)
• Every prescriber is comfortable prescribing to adolescents (many endocrinologists and paediatricians are still developing practice protocols)
• There are no long-term unknowns (adolescent use is newer; long-term follow-up data is limited)

In practice, adolescent GLP-1 prescriptions are typically initiated by paediatric endocrinologists or obesity medicine specialists, not primary care, and typically include a multidisciplinary component (dietary counselling, behavioural support).

Adolescent-specific considerations

Growth and development

GLP-1 receptors are expressed in the growth plate and bone. The theoretical concern is that appetite suppression combined with reduced caloric intake during active growth could impair linear growth (height) or bone density accumulation.

Current evidence: STEP TEENS showed normal height growth velocity maintained over 68 weeks on semaglutide — growth was not impaired. Bone density was not formally assessed as a primary endpoint. Longer-term bone density monitoring is an active area of study.

Practical implication: Adolescents on GLP-1 therapy should have height tracked regularly. If growth velocity slows (less than 4 cm/year for children under 15, for example), this warrants discussion with the prescriber.

Nutritional adequacy during growth

Adolescents have higher nutritional demands per kg than adults — not just calories, but micronutrients relevant to growth (calcium, vitamin D, zinc, iron). Appetite suppression that reduces nutritional adequacy during a critical growth window is a legitimate concern.

Recommendation: Nutritional assessment and supplementation guidance should be part of adolescent GLP-1 management, not an afterthought.

Eating disorder risk

Eating disorders have peak onset in adolescence. GLP-1 therapy in adolescents requires careful screening for pre-existing restrictive eating disorders or subclinical disordered eating patterns, because appetite suppression on a background of restriction can be clinically dangerous.

Screening tools such as the SCOFF questionnaire or NIAS (Night Eating Syndrome Assessment Scale, adapted for ED screening) should be part of pre-prescribing assessment for adolescents.

Long-term pharmacological dependence

Unlike many paediatric medications, GLP-1 therapy for obesity is likely to require indefinite continuation — weight regain on discontinuation is well documented. Adolescents starting at 12–16 are committing to a potential lifetime of treatment. This should be part of the informed consent discussion.

Insurance coverage challenges for adolescents

Many commercial insurance plans and Medicaid programmes that cover Wegovy or Zepbound for adults have specific exclusions or prior authorisation criteria for paediatric patients. Coverage is inconsistent and often lags the FDA approval by 1–2+ years.

The practical result: many families pursuing GLP-1 treatment for adolescents face cash-pay costs or extensive prior authorisation battles even with FDA approval in place.

Who should be prescribing to adolescents

Current clinical guidance (American Academy of Paediatrics, Endocrine Society) recommends adolescent GLP-1 prescribing be:

• Initiated by a specialist (paediatric endocrinology, adolescent medicine, or obesity medicine)
• Part of a comprehensive programme including lifestyle counselling
• Accompanied by regular monitoring (height, weight, labs, nutritional status)
• Not initiated in patients with active eating disorders, active thyroid disease, or personal/family history of MTC

Summary

Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for adolescents aged 12 and older with obesity. Trial data shows comparable weight loss to adult outcomes. Adolescent-specific considerations include growth monitoring, nutritional adequacy during development, eating disorder screening, and the long-term treatment commitment. Prescribing should be initiated by a specialist with a comprehensive support structure. Insurance coverage for adolescents remains variable and often requires additional authorisation.

This article is queued for review by a medical doctor. It should not be used as personal medical advice.